(130 days)
Not Found
No
The summary describes a vision test based on shape discrimination hyperacuity and a notification system for physicians. There is no mention of AI, ML, or any related concepts like training sets, deep learning, or image processing that would typically indicate the use of such technologies for analysis or interpretation. The performance studies focus on usability and comparison to a predicate device, not on the performance of an AI/ML algorithm.
No
The device is intended for detection and monitoring, not for providing treatment or therapy. It aids in diagnosis and monitoring but does not directly treat the condition.
No
The device is intended for detection and monitoring, and explicitly states it is "not intended to diagnose; diagnosis is the responsibility of the prescribing eye-care professional."
Yes
The device is described as a "downloadable app on to the user's supplied cell phone or tablet," indicating it is software that runs on existing hardware provided by the user. There is no mention of proprietary hardware included with the device.
Based on the provided information, the myVisionTrack® Model 0005 is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- myVisionTrack® Model 0005 Function: The myVisionTrack® Model 0005 is a vision function test that uses a downloadable app on a personal device. It assesses visual distortion (metamorphopsia) by having the patient perform a self-test. It does not involve the collection or analysis of any biological specimens from the patient's body.
- Intended Use: The intended use clearly states it's for the "detection of central 3 degrees metamorphopsia" and "monitoring progression of disease factors causing metamorphopsia." While this information is used to aid in monitoring and potentially inform the physician, it's based on the patient's visual perception and response to a visual stimulus, not on the analysis of a biological sample.
- No Specimen Handling: The description of the device and its use does not mention any steps involving the collection, preparation, or analysis of biological specimens.
Therefore, the myVisionTrack® Model 0005 falls under the category of a medical device, but not specifically an In Vitro Diagnostic device. It's a device that directly interacts with the patient's sensory system (vision) to assess a physiological function.
N/A
Intended Use / Indications for Use
The myVisionTrack® Model 0005 is intended for the detection of central 3 degrees metamorphopsia (visual distortion) in patients with maculopathy, including age-related macular degeneration and diabetic retinopathy, and as an aid in monitoring progression of disease factors causing metamorphopsia. It is intended to be used by patients who have the capability to regularly perform a simple self-test at home. The myVisionTrack® Model 0005 is not intended to diagnose; diagnosis is the responsibility of the prescribing eye-care professional.
Product codes (comma separated list FDA assigned to the subject device)
HOQ
Device Description
The myVisionTrack® Model 0005 is a vision function test provided as a downloadable app on to the user's supplied cell phone or tablet. The myVisionTrack® Model 0005 implements a shape discrimination hyperacuity (SDH) vision test which allows patients to perform their own vision test at home. If a significant worsening of vision function is detected the physician will be notified and provided access to the vision self-test results so that they can decide whether the patient needs to be seen sooner than their next already scheduled appointment.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
central 3 degrees
Indicated Patient Age Range
Not Found
Intended User / Care Setting
patients who have the capability to regularly perform a simple self-test at home.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation of the software confirmed that the software performs as intended.
A Usability Study was independently performed with 10 subjects (5 normal and 5 with maculopathy). Participants ranged in age from 19 to 68. The usability study concluded that with a training session demo, users should not encounter any difficulties completing the self-test. Participants reported no complaints on device or myVisionTrack® Model 0005. All participants did meet the 90% criteria of taking the vision self-test without encountering any issues that prevented them from completing the test. 90% of participants understood how to access the "More" screen and additional functions. 80% were able to complete the vision self-test in less than 10 minutes.
A Cross-sectional Study was also performed with 86 subjects (40 with normal vision and 46 with various types of maculopathy) to do a direct comparison of the myVisionTrack® Model 0003 to the myVisionTrack® Model 0005. The study concluded that the performance of the myVisionTrack® Model 0005 employing a 4AFC testing paradigm is not significantly different from that of myVisionTrack® Model 0003 using a 3AFC testing paradigm. The test results obtained with these two models are comparable with each other. While there is a slight bias of approximately 0.06 logRM (log10 of Radial Modulation amplitude) worse results for the myVisionTrack® Model 0005 measurements compared to myVisionTrack® Model 0003. This bias is not surprising and it agrees with the design hypothesis that 4AFC paradigm reduces the chance level (lucky guesses) when compared with 3AFC, so that it reduces the likelihood of overestimating patients' ability to detect distortion in a shape discrimination task, which will in fact allow myVisionTrack® Model 0005 to obtain more reliable self-testing results.
Additionally 4 patients with maculopathy were tested using an iPod Touch (3AFC), an iPad air (4AFC, circular arrangement of stimulus patterns) and an iPhone 6+ (4AFC, rectangular arrangement of stimulus patterns) to confirm performance across device platforms. The test results demonstrated that the test variability across different devices is comparable or smaller than 0.10 logRM, which is the test variability over time for the mVT™ test. The mean results across all patients are -2.11 logRM, -2.07 logRM, and -2.07 logRM for iPod Touch, iPad air, and iPhone 6+, respectively, which is not significantly different from each other (F=0.047, p>0.95).
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 886.1330 Amsler grid.
(a)
Identification. An Amsler grid is a device that is a series of charts with grids of different sizes that are held at 30 centimeters distance from the patient and intended to rapidly detect central and paracentral irregularities in the visual field.(b)
Classification. Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 886.9. The device is also exempt from the current good manufacturing practice requirements of the quality system regulation in part 820 of this chapter, with the exception of § 820.180, with respect to general requirements concerning records, and § 820.198, with respect to complaint files.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized graphic of three human profiles facing right, with flowing lines representing hair or fabric.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
March 20, 2015
Vital Art and Science, LLC. c/o Ms. Maureen O'Connell President O'Connell Regulatory Consultants, Inc. 5 Timber Lane North Reading, MA 01864
Re: K143211
Trade/Device Name: myVisionTrack® Model 0005 Regulation Number: 21 CFR 886.1330 Regulation Name: Amsler grid Regulatory Class: Class I Product Code: HOO Dated: February 13, 2015 Received: February 18, 2015
Dear Ms. O'Connell:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies.
1
You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801 and Part 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and Part 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Kesia Y. Alexander -S
for Malvina B. Eydelman, MD Director. Division of Ophthalmic and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known)
Device Name myVisionTrack® Model 0005
Indications for Use (Describe)
The my VisionTrack® Model 0005 is intended for the detection of central 3 degrees metamorphopsia (visual distortion) in patients with maculopathy, including age-related macular degeneration and diabetic retinopathy, and as an aid in monitoring progression of disease factors causing metamorphopsia. It is intended to be used by patients who have the capability to regularly perform a simple self-test at home. The myVisionTrack® Model 0005 is not intended to diagnose; diagnosis is the responsibility of the prescribing eye-care professional.
Type of Use (Select one or both, as applicable):
| x Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| □ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(k) Summary
| Date prepared: | March 20, 2015 |
|---|---|
| 510(k) Owner: | Vital Art and Science, LLC |
| 2725 N. Spring Drive | |
| Richardson, TX 75082-4233 | |
| Phone: 214-989-7130 | |
| Contact Person: | Maureen O'Connell |
| O'Connell Regulatory Consultants, Inc | |
| 5 Timber Lane | |
| North Reading, MA 01864 | |
| Phone: 978-207-1245 | |
| Fax: 978-824-2541 |
Name of the Device and Classification
| Type of 510(k) Submission: | Traditional |
|---|---|
| Trade Name: | myVisionTrack® Model 0005 |
| Common Name: | Home vision function monitor |
| Regulation Number: | 21 CFR 886.1330 |
| Regulation Name: | Amsler grid |
| Regulatory Class: | Class I |
| Product Code: | HOQ |
Predicate Devices:
The Vital Art and Science, LLC myVisionTrack® Model 0005 (mVTTM) is substantially equivalent to the following predicate medical device:
- myVisionTrack® Model 0003 supplied by Vital Art and Science Incorporated; Perimeter, Automatic, AC-Powered, 21 CFR 886.1605; K121738; Product Code: HPT
4
Device Description:
The myVisionTrack® Model 0005 is a vision function test provided as a downloadable app on to the user's supplied cell phone or tablet. The myVisionTrack® Model 0005 implements a shape discrimination hyperacuity (SDH) vision test which allows patients to perform their own vision test at home. If a significant worsening of vision function is detected the physician will be notified and provided access to the vision self-test results so that they can decide whether the patient needs to be seen sooner than their next already scheduled appointment.
The test images used by myVisionTrack® Model 0005 are shown below. The distorted version is created by modulating the radius of the circle with a sinusoid. The user is shown four circles and asked to identify the distorted circle
Image /page/4/Picture/3 description: The image shows a black smartphone with a gray screen. On the screen, there are three circles and one star-shaped figure. The circles are arranged in a vertical line on the left side of the screen, while the star is on the right side.
Indications for Use:
The myVisionTrack® Model 0005 is intended for the detection and characterization of central 3 degrees metamorphopsia (visual distortion) in patients with maculopathy. including age-related macular degeneration and diabetic retinopathy, and as an aid in monitoring progression of disease factors causing metamorphopsia. It is intended to be used by patients who have the capability to regularly perform a simple self-test at home.
5
The my VisionTrack® is not intended to diagnose; diagnosis is the responsibility of the prescribing eye-care professional.
Indications for Use as compared to the Predicate Device:
The Indications for Use is identical to the Indications for User for the Predicate Device.
Substantial Equivalence Comparison
The myVisionTrack® Model 0005 is a modification to the myVisionTrack® Model 0003 (K121738) which was cleared in February, 2013. The myVisionTrack® Model 0005 has the same intended use and indications for use, principles of operation, and similar technological characteristics as the previously cleared predicate. The major elements of the technology remain unchanged. The target population and the area of vision monitored is identical between the two devices. The vision test algorithm used and the test algorithm implementation is identical between the two devices.
The two devices are identical with the exception of the differences which are as follows:
Hardware Platform and Display Resolution: The my VisionTrack® Model 0003 was delivered as an app already installed on an Apple iPhone 4S device. The myVisionTrack® Model 0005 will be distributed as an app for a user supplied device including the following devices:
iPhone 4s, 5, 5c, 5s, 6, 6+ iPod Touch 4, 5 iPad 2, 3, 4 iPad Air, Air 2 iPad mini, mini 2/3 (retina) iOS Support is iOS 6, 7, and 8
Some of the older devices have a lower pixels/degree than the previously cleared iPhone 4S, but previously conducted clinical studies on these devices have demonstrated there is no significant difference in the clinical results.
The my VisionTrack® Model 0005 only runs on hardware and operating systems that have been fully validated and approved by Vital Art and Science, LLC. This is controlled by doing a check on start-up of the app and comparing against a list of approved hardware and iOS.
Method Supplied: The myVisionTrack® Model 0003 was supplied with the necessary hardware while the myVisionTrack® Model 0005 will be provided as an app available on the Apple iTunes store. Instructions for how to download, install and unlock the app will be provided on the Rx provided by the Prescribing Doctor through a secure portal. These
6
printed instructions will also point the user towards Vital Art and Science, LLC's website, where there will be detailed instructions and videos on how to download, install and take the test. The Rx will also have information on how to access our 24/7 support center for any additional help they may need.
Data Upload Capability: The myVisionTrack® Model 0003 was being supplied with a device that was already set-up with a cellular data connection. In the myVisionTrack® Model 0005, the patient will be supplying the Apple device including the connection to the internet.
Number of test circles: The myVisionTrack® Model 0003 was limited to a maximum of 3 displayed test circles by the small display size of the iPhone Models 1 - 3. All of the original development work and initial studies were done on these smaller devices. Since the iPhone 4 the size of the display is such that we can fit in 4 test circles. It is desirable to transition to a 4 circle test because it reduces the "chance level" of the user guessing the correct circle from 33% to 25% and so improves the accuracy of the test. The underlying methodology and science of the test remains unchanged. The only change made here is to change from a "3 alternative forced choice" or 3AFC algorithm to a "4 alternative forced choice" or 4AFC algorithm.
Orientation of Display: In the my VisionTrack® Model 0003 users had been encouraged to test using 2 hands to hold the device in a "landscape" orientation. As Apple has come out with larger devices, such as the iPad and iPad mini, and added more features including the "front facing camera" it has become clear to us that most patients are more comfortable holding the device in a "portrait" orientation. This is the standard orientation for holding the iPhone when making phone calls, and using most other functions.
Method of managing "by Rx Only": The myVisionTrack® Model 0003 was controlled through physical management of the devices themselves. With the change to a downloadable app for the myVisionTrack® Model 0005 a different method is required to limit access to the app to those with a valid prescription, and to insure the test results and alerts are delivered to that prescribing doctor. The method implemented in the myVisionTrack® Model 0005 is to use a 10 digit Rx Code. This code is generated on Vital Art and Science, LLC's secure Portal by the prescribing doctor, or someone on their staff. This is a one-time-use code that is invalid for any additional user once it has been used. The code is printed automatically from the Portal at the time the device is prescribed, and once it is used to unlock the app it provides the connection required to insure that all test results are attributed to that patient, and results delivered to their prescribing doctor.
7
Who can prescribe: The myVisionTrack® Model 0003 was cleared for Prescription Use only by order of a physician (MD or DO). Since the bulk of eve care is provided by Optometrists (ODs) in the United States, Vital Art wants to allow ODs to prescribe the app as well.
In conclusion, the proposed myVisionTrack® Model 0005 as compared to the already cleared Model 0003 predicate device has:
- Identical indications for use;
- . Similar physical composition, in that both use visual testing software delivered on a validated hardware platform and operating system;
- . A more traditional prescription method where the doctor delivers a paper Rx with instructions on how to download and install the app instead of delivering a device with the app already installed;
- . An identical vision test algorithm, but with the change from 3 to 4 choices of displayed images:
- . An identical method of operation for the patient to perform self-testing at home; and
- . An identical central monitoring of patient self-test results, with a new method to insure test results and alerts are being delivered only to their prescribing doctor.
Therefore the myVisionTrack® Model 0005 is substantially equivalent to the predicate device.
Performance Data
Verification and validation of the software confirmed that the software performs as intended. A Usability Study was independently performed with 10 subjects (5 normal and 5 with maculopathy) and concluded that subjects could effectively self-test their vision and that they found the device to be user-friendly. Participants ranged in age from 19 to 68. The usability study concluded that with a training session demo, users should not encounter any difficulties completing the self-test. Participants reported no complaints on device or myVisionTrack® Model 0005. All participants did meet the 90% criteria of taking the vision self-test without encountering any issues that prevented them from completing the test. 90% of participants understood how to access the "More" screen and additional functions. 80% were able to complete the vision self-test in less than 10 minutes.
A Cross-sectional Study was also performed with 86 subjects (40 with normal vision and 46 with various types of maculopathy) to do a direct comparison of the myVisionTrack® Model 0003 to the myVisionTrack® Model 0005. The study concluded that the performance of the myVisionTrack® Model 0005 employing a 4AFC testing paradigm is not significantly different from that of myVisionTrack® Model 0003 using a 3AFC testing paradigm. The test results obtained with these two models are comparable with each other. While there is a slight bias of approximately 0.06 logRM (log10 of Radial Modulation amplitude) worse results for the myVisionTrack® Model 0005 measurements compared to myVisionTrack® Model 0003. This bias is not surprising and
8
it agrees with the design hypothesis that 4AFC paradigm reduces the chance level (lucky guesses) when compared with 3AFC, so that it reduces the likelihood of overestimating patients' ability to detect distortion in a shape discrimination task, which will in fact allow myVisionTrack® Model 0005 to obtain more reliable self-testing results. Additionally 4 patients with maculopathy were tested using an iPod Touch (3AFC), an iPad air (4AFC, circular arrangement of stimulus patterns) and an iPhone 6+ (4AFC, rectangular arrangement of stimulus patterns) to confirm performance across device platforms. The test results demonstrated that the test variability across different devices is comparable or smaller than 0.10 logRM, which is the test variability over time for the mVT™ test. The mean results across all patients are -2.11 logRM, -2.07 logRM, and -2.07 logRM for iPod Touch, iPad air, and iPhone 6+, respectively, which is not significantly different from each other (F=0.047, p>0.95).